6978.HK Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (2 Jun 2024 @ 23:22):

Stats
Today's Volume	101 000
Average Volume	53 751.00
Market Cap	1.53B
EPS	HKD0 ( 2024-03-28 )
Last Dividend	HKD0 ( N/A )
Next Dividend	HKD0 ( N/A )
P/E	-4.20
ATR14	HKD0.0750 (2.52%)

Immunotech Biopharm Ltd Correlation

10 Most Positive Correlations

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Immunotech Biopharm Ltd Financials

Annual	2023
Revenue:	HKD0
Gross Profit:	HKD0 (0.00 %)
EPS:	HKD-0.650

FY	2023
Revenue:	HKD0
Gross Profit:	HKD0 (0.00 %)
EPS:	HKD-0.650

FY	2022
Revenue:	HKD0
Gross Profit:	HKD0 (0.00 %)
EPS:	HKD-0.690

FY	2021
Revenue:	HKD0.00
Gross Profit:	HKD0.00 (0.00 %)
EPS:	HKD-0.708

Financial Reports:

No articles found.

Immunotech Biopharm Ltd Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Immunotech Biopharm Ltd

Immunotech Biopharm Ltd, a cellular immunotherapy biopharmaceutical company, focuses on the research, development, and commercialization of T cell immunotherapy products for the treatment of cancers in the People's Republic of China. Its core product is EAL, a multi-target cellular immunotherapy product that is in Phase II clinical trials for the prevention of postsurgical recurrence of liver cancer. The company is also conducting pre-clinical and clinical trial studies for EAL to treat lung cancer, glioma, gastric cancer, and colorectal cancer. In addition, it develops 6B11-OCIK injection that is in Phase I clinical trial for ovarian cancer; CAR-T-19 injection product for B-cell acute lymphoblastic leukaemia; and TCR-T cell series products to treat solid tumors. The company was founded in 2006 and is headquartered in Beijing, the People's Republic of China.